Eli Lilly Extends Partnership With Insilico Medicine For AI Powered Drug Discovery
Eli Lilly has expanded its collaboration with Insilico Medicine in a deal valued at up to 2.75 billion dollars. The agreement strengthens their ongoing work in artificial intelligence driven drug discovery. Insilico announced the development on Sunday, confirming that the partnership builds on earlier arrangements between the two companies.
Expanded Scope Of AI Driven Research
Under the updated agreement, Lilly will use Insilico’s artificial intelligence engine to support drug development. In addition, Lilly will gain exclusive worldwide rights to develop, manufacture, and commercialise certain oral treatments. These treatments are currently in the preclinical stage, which means researchers are still evaluating their safety and effectiveness before human trials.
Moreover, the collaboration focuses on applying AI technologies across multiple stages of research. This approach allows scientists to identify biological targets linked to several diseases at once. As a result, the companies aim to improve efficiency and broaden the impact of new treatments.
Financial Terms And Milestone Payments
The financial structure of the deal reflects both immediate and long term commitments. Insilico will receive an upfront payment of 115 million dollars. Furthermore, the company may earn additional payments tied to development, regulatory, and commercial milestones. These staged payments could raise the total value of the agreement to approximately 2.75 billion dollars.
In addition, Insilico will receive tiered royalties on future product sales. This structure ensures that both companies share the financial benefits if the treatments succeed in the market.
Ongoing Collaboration And Strategic Goals
This agreement follows a research collaboration signed in November. That deal had already expanded a partnership that began in 2023 with an AI based software licensing arrangement. Therefore, the latest development marks another step in a steadily growing relationship.
According to Insilico’s leadership, the use of scalable AI systems plays a central role in the partnership. These systems aim to model biological processes more effectively, which may accelerate the identification of promising drug targets. Consequently, both companies seek to streamline drug discovery while addressing multiple diseases simultaneously.
With inputs from Reuters